For immediate release – Palo Alto, CA – July 3, 2026

On June 5, 2026, Bravo Innovator Award winner EllieMD launched a line of Hormone Replacement Therapy (HRT) products designed to serve the 50 million U.S. women experiencing symptoms of menopause. This launch positions the company at the forefront of one of the most significant shifts in women’s health by giving self-health options to the nearly 75% of menopausal women who do not receive care for their symptoms.

This launch comes quickly after the FDA’s changes to HRT guidelines that removed unsubstantiated warnings from the label.

EllieMD's HRT launch represents more than the addition of a new product category. It reflects the company's commitment to pioneering self-health for people struggling to find solutions for their wellness needs. EllieMD has consistently anticipated where healthcare is headed. By combining telehealth, trusted medical providers, and a relationship-driven distribution model, EllieMD continues to reinvent how consumers access care, placing personal empowerment at the center of the healthcare experience.

“Women spent decades paying the price for outdated information. Millions were told to fear therapies that, for many, could have meaningfully improved their quality of life and health span, while countless suffered in silence. HRT is more than a product launch for us. It's a reminder to ask a much bigger question: What other preventative therapies are people missing because science hasn't caught up with perception?

That's the mission we've dedicated EllieMD to. We are building the future of community-powered health by making evidence-based, physician-guided preventative care more accessible, more personalized, and available long before disease begins. We'll continue challenging old thinking, advocating for our communities, and fighting to bring better healthcare to everyone.”

—Hanieh Sigari, Founder & CEO, EllieMD